First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial - 30/08/23
, Saadettin Kilickap, ProfMD b, †, Ahmet Sezer, ProfMD c, Mahmut Gümüş, ProfMD d, Igor Bondarenko, ProfMD e, Miranda Gogishvili, MD f, Marina Nechaeva, MD g, Michael Schenker, ProfMD h, Irfan Cicin, ProfMD i, Gwo Fuang Ho, ProfMD j, Yaroslav Kulyaba, MD k, Kasimova Zyuhal, MD l, Roxana-Ioana Scheusan, MD m, Marina Chiara Garassino, ProfMD n, Xuanyao He, PhD o, Manika Kaul, MD o, Emmanuel Okoye, MPH o, Yuntong Li, PhD o, Siyu Li, PhD o, Jean-Francois Pouliot, PhD o, Frank Seebach, MD o, Israel Lowy, MD o, Giuseppe Gullo, MD o, Petra Rietschel, MD oSummary |
Background |
Cemiplimab provided significant survival benefit to patients with advanced non-small-cell lung cancer with PD-L1 tumour expression of at least 50% and no actionable biomarkers at 1-year follow-up. In this exploratory analysis, we provide outcomes after 35 months' follow-up and the effect of adding chemotherapy to cemiplimab at the time of disease progression.
Methods |
EMPOWER-Lung 1 was a multicentre, open-label, randomised, phase 3 trial. We enrolled patients (aged ≥18 years) with histologically confirmed squamous or non-squamous advanced non-small-cell lung cancer with PD-L1 tumour expression of 50% or more. We randomly assigned (1:1) patients to intravenous cemiplimab 350 mg every 3 weeks for up to 108 weeks, or until disease progression, or investigator's choice of chemotherapy. Central randomisation scheme generated by an interactive web response system governed the randomisation process that was stratified by histology and geographical region. Primary endpoints were overall survival and progression free survival, as assessed by a blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumours version 1.1. Patients with disease progression on cemiplimab could continue cemiplimab with the addition of up to four cycles of chemotherapy. We assessed response in these patients by BICR against a new baseline, defined as the last scan before chemotherapy initiation. The primary endpoints were assessed in all randomly assigned participants (ie, intention-to-treat population) and in those with a PD-L1 expression of at least 50%. We assessed adverse events in all patients who received at least one dose of their assigned treatment. This trial is registered with ClinicalTrials.gov, NCT03088540.
Findings |
Between May 29, 2017, and March 4, 2020, we recruited 712 patients (607 [85%] were male and 105 [15%] were female). We randomly assigned 357 (50%) to cemiplimab and 355 (50%) to chemotherapy. 284 (50%) patients assigned to cemiplimab and 281 (50%) assigned to chemotherapy had verified PD-L1 expression of at least 50%. At 35 months' follow-up, among those with a verified PD-L1 expression of at least 50% median overall survival in the cemiplimab group was 26·1 months (95% CI 22·1–31·8; 149 [52%] of 284 died) versus 13·3 months (10·5–16·2; 188 [67%] of 281 died) in the chemotherapy group (hazard ratio [HR] 0·57, 95% CI 0·46–0·71; p<0·0001), median progression-free survival was 8·1 months (95% CI 6·2–8·8; 214 events occurred) in the cemiplimab group versus 5·3 months (4·3–6·1; 236 events occurred) in the chemotherapy group (HR 0·51, 95% CI 0·42–0·62; p<0·0001). Continued cemiplimab plus chemotherapy as second-line therapy (n=64) resulted in a median progression-free survival of 6·6 months (6·1–9·3) and overall survival of 15·1 months (11·3–18·7). The most common grade 3–4 treatment-emergent adverse events were anaemia (15 [4%] of 356 patients in the cemiplimab group vs 60 [17%] of 343 in the control group), neutropenia (three [1%] vs 35 [10%]), and pneumonia (18 [5%] vs 13 [4%]). Treatment-related deaths occurred in ten (3%) of 356 patients treated with cemiplimab (due to autoimmune myocarditis, cardiac failure, cardio-respiratory arrest, cardiopulmonary failure, septic shock, tumour hyperprogression, nephritis, respiratory failure, [n=1 each] and general disorders or unknown [n=2]) and in seven (2%) of 343 patients treated with chemotherapy (due to pneumonia and pulmonary embolism [n=2 each], and cardiac arrest, lung abscess, and myocardial infarction [n=1 each]). The safety profile of cemiplimab at 35 months, and of continued cemiplimab plus chemotherapy, was generally consistent with that previously observed for these treatments, with no new safety signals
Interpretation |
At 35 months' follow-up, the survival benefit of cemiplimab for patients with advanced non-small-cell lung cancer was at least as pronounced as at 1 year, affirming its use as first-line monotherapy for this population. Adding chemotherapy to cemiplimab at progression might provide a new second-line treatment for patients with advanced non-small-cell lung cancer.
Funding |
Regeneron Pharmaceuticals and Sanofi.
Le texte complet de cet article est disponible en PDF.Plan
Vol 24 - N° 9
P. 989-1001 - septembre 2023 Retour au numéro
Article précédent
- Effect of paediatric early warning systems (PEWS) implementation on clinical deterioration event mortality among children with cancer in resource-limited hospitals in Latin America: a prospective, multicentre cohort study
- Asya Agulnik, Hilmarie Muniz-Talavera, Linh T D Pham, Yichen Chen, Angela K Carrillo, Adolfo Cárdenas-Aguirre, Alejandra Gonzalez Ruiz, Marcela Garza, Tania Maria Conde Morelos Zaragoza, Dora Judith Soberanis Vasquez, Alejandra Méndez-Aceituno, Carlos Acuña-Aguirre, Yvania Alfonso-Carreras, Shillel Yahamy Alvarez Arellano, Leticia Aradi Andrade Sarmiento, Rosario Batista, Erika Esther Blasco Arriaga, Patricia Calderon, Mayra Chavez Rios, María Eugenia Costa, Rosdali Díaz-Coronado, Ever Amilcar Fing Soto, Wendy Cristhyna Gómez García, Martha Herrera Almanza, Maria Susana Juarez Tobías, Esmeralda Mercedes León López, Norma Araceli López Facundo, Ruth Angelica Martinez Soria, Kenia Miller, Scheybi Teresa Miralda Méndez, Lupe Nataly Mora Robles, Natalia del Carmen Negroe Ocampo, Berenice Noriega Acuña, Alejandra Osuna Garcia, Carlos M Pérez Alvarado, Clara Krystal Pérez Fermin, Estuardo Enrique Pineda Urquilla, Carlos Andrés Portilla Figueroa, Ligia Estefanía Ríos Lopez, Jocelyn Rivera Mijares, Verónica Soto Chávez, Jorge Iván Suarez Soto, Juliana Teixeira Costa, Isidoro Tejocote Romero, Erika Elena Villanueva Hoyos, Marielba Villegas Pacheco, Meenakshi Devidas, Carlos Rodriguez-Galindo, EVAT Study Group
- Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
- Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo, Jaromir Roubec, Lubos Petruzelka, Libor Havel, Sujith Kalmadi, Jeffrey Ward, Zoran Andric, Thierry Berghmans, David E Gerber, Goetz Kloecker, Rajiv Panikkar, Joachim Aerts, Angelo Delmonte, Miklos Pless, Richard Greil, Christian Rolfo, Wallace Akerley, Michael Eaton, Mussawar Iqbal, Corey Langer, LUNAR Study Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?